2 weeks ago
9
Soumya Eswaran
Fri, April 17, 2026 astatine 9:37 AM CDT 3 min read
Michigan-based concern advisor Cedar Grove Capital Management precocious released its archetypal 4th 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. Cedar Grove Capital Management’s Multi-Strategy Composite posted a -23.0% nett instrumentality since inception, compared to -5.6% for the Russell 2000, -5.9% for the Russell Microcap, and -5.5% for the S&P 500. Timing is cardinal for aboriginal money success, yet predicting outer shocks during volatile macroeconomic periods is impossible. Rather than speculate connected macro risks, it’s advisable to put successful beardown companies astatine tenable prices with bully maturation prospects. The caller downturn, called a "SaaS apocalypse," was an accidental to bargain prime stocks that were undervalued contempt amended fundamentals and imaginable AI-driven gains. In February and aboriginal March, astir each portfolio holdings reported beardown earnings. However, the outbreak of warfare successful Iran rapidly overshadowed these gains, causing a accelerated marketplace selloff. While macro factors wounded show successful Q1, the steadfast is assured that its companies volition bash good successful Q2 and beyond. In addition, delight cheque the Strategy’s apical 5 holdings to cognize its champion picks successful 2026.
In its first-quarter 2026 capitalist letter, Cedar Grove Capital Management highlighted stocks similar Hims & Hers Health, Inc. (NYSE:HIMS). Hims & Hers Health, Inc. (NYSE:HIMS) is simply a starring telehealth level that offers a scope of curated medicine and non-prescription wellness and wellness products and services. On April 16, 2026, Hims & Hers Health, Inc. (NYSE:HIMS) closed astatine $26.99 per share. One-month instrumentality of Hims & Hers Health, Inc. (NYSE:HIMS) was 33.24%, and its shares gained 7.75% implicit the past 52 weeks. Hims & Hers Health, Inc. (NYSE:HIMS) has a marketplace capitalization of $6.15 billion.
Cedar Grove Capital Management stated the pursuing regarding Hims & Hers Health, Inc. (NYSE:HIMS) successful its Q1 2026 capitalist letter:
"Hims & Hers Health, Inc. (NYSE:HIMS): If you’ve known america for adjacent a small bit, you’ve astir apt known our sum of this sanction from a bearish constituent of presumption since January 2025. Our continued notes connected the sanction past year, connected the institution relying heavy connected their compounded GLP-1 offering to offset a decelerating halfway business, allowed for aggregate opportunities to recognize gains connected the abbreviated side. Needless to say, Andrew (CEO) yet did alert excessively adjacent to the prima and was inevitably sued for IP infringement by Novo Nordisk (NVO) successful February of this year. A large intelligence triumph for us. On the time of earnings, we entered into our latest abbreviated presumption successful the institution and rapidly realized gains the pursuing greeting connected questionable guidance and net telephone hype than reassurance. We person not had immoderate different presumption with the institution since, but we did item HIMS displacement distant from GLP-1s going forward."
English (CA) · 
English (US) · 
Spanish (MX) ·